Skip to main content

Madrigal Pharmaceuticals, Inc.

corporate_fare Company Profile

Madrigal Pharmaceuticals, Inc.

MDGL·NASDAQ·Life Sciences·CIK 0001157601

The company is a biopharmaceutical company focused on developing new treatments for metabolic dysfunction-associated steatohepatitis ("MASH"), a serious liver disease. MASH was previously known as nonalcoholic steatohepatitis ("NASH"). MASH is the leading cause of liver transplantation in women, the second leading cause of all liver transplantation in the United States, and the fastest-growing indication for liver transplantation in Europe. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta ("THR-β") agonist designed to target key underlying causes of MASH. In March 2024, Rezdiffra became the first therapy approved by the FDA for patients with MASH and was commercially available in the United States starting in April 2024. Following conditional marketing authorization ("CMA") from the European Commission ("EC"), the company launched Rezdiffra in Germany in September 2025. Rezdiffra was the first medication approved by both the FDA and EC for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3 fibrosis). The company is also evaluating Rezdiffra in patients with compensated MASH cirrhosis (consistent with F4c fibrosis) in its MAESTRO-NASH OUTCOMES trial. Additionally, the company is developing a focused pipeline of MASH treatments. Through business development, it has acquired rights to MGL-2086, an oral glucagon-like peptide-1 ("GLP-1") receptor agonist, ervogastat, an oral diacylglycerol O-acyltransferase 2 ("DGAT2") inhibitor, six small interfering RNA ("siRNA") programs, and additional preclinical MASH candidates. For the year ended December 31, 2025, the company generated $958.4 million in product revenue from sales of Rezdiffra.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for MDGL at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Madrigal Gains Full Control Over Rezdiffra Patent Extensions from Roche

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$958.4M
Net Income
-$288.28M
Diluted EPS
-$12.85
Op. Cash Flow
-$189.55M
Free Cash Flow
-$190.02M
Operating Income
-$300.1M
Cash & Equivalents
$198.69M
Total Debt
$339.88M
Debt / Equity
0.56×
Net Margin
-30.1%
Shares Outstanding
22.84M sh
Source: 10-K · filed 2026-02-19 · accession 0001628280-26-009514
$379.1
52-week range · as of 2026-11-06 $353.54 – $615
Market cap
$8.81B
Volume
327.8K (0.6× avg)
3-mo avg 521.2K
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MDGL - Filings & News (Page 2)

MDGL
Jan 30, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $489.31
Real-time Price: $379.10 info
Change: -$110.21 (-23%) info
Market Cap: $8.806B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets